【制药网 行业动态】近日,阿斯利康宣布终止三项细胞疗法合作管线,分别是通过收购得到的TCR-T疗法NT-125,以及两款CAR-T疗法AZD5851和AZD6422。其中,NT-125是2022年阿斯利康收购NeogeneTherapeutics时获得的核心TCR-T疗法之一,主要用于治疗非小细胞肺癌、结直肠腺癌、头颈部鳞状细胞癌等多种实体瘤,而阿斯利康给出的放弃理由是对细胞疗法产品组合进行战略...
Source Link【制药网 行业动态】近日,阿斯利康宣布终止三项细胞疗法合作管线,分别是通过收购得到的TCR-T疗法NT-125,以及两款CAR-T疗法AZD5851和AZD6422。其中,NT-125是2022年阿斯利康收购NeogeneTherapeutics时获得的核心TCR-T疗法之一,主要用于治疗非小细胞肺癌、结直肠腺癌、头颈部鳞状细胞癌等多种实体瘤,而阿斯利康给出的放弃理由是对细胞疗法产品组合进行战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.